August 18 (UPI) – A Chinese vaccine manufacturer said the company would be in a position to implement a coronavirus vaccine until the end of the year.
Advanced stage testing with human subjects began on August 11. According to Sinopharm, if approved, the company expects 120 million doses a year to be produced at the Beijing Bio-Institute of Biological Products and another hundred million doses at Wuhan Institute. biological products.
Sinopharm President Liu Jingzhen said in an interview with state media that his corporate plans to make the vaccine available to the public until the end of December after approval. Liu also said two doses of vaccine would provide “100% immunity,” at a cost of about $144.
“It will be constant at a very high price,” he said.
Last week, an article published in the Journal of the American Medical Association said the Sinopharm vaccine is and generates an immune response, China State News Firm Xinhua reported Sunday.
The effects came here from an intermediate investigation of the Phase 1 and 2 trials of the Sinopharm vaccine. Patients showed no effects, according to the article.